Selected publications

  • Pastor F, Berraondo P, Etxberria I, Frederick J, Shain U, Gilboa E, Melero I*. An RNA Tool-Box For Cancer Immunotherapy. Nature Review Drug Discovery. 2018 ;17(10):751-767.

  • Soldevilla MM, Villanueva H,  Martinez-Velez N, Meraviglia-Crivelli D, Alonso MM, Cebollero J, Menon AP, Pastor F*. Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors. Oncoimmunology. 2018 9;7(8):e1450711.

  • Soldevilla MM, Hervas S, Villanueva H, Lozano T, Rabal O, Oyarzabal J, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA). PlosOne. 2017;12(9):e0185169.

  • Lozano,  Soldevilla MM, Casares N, Villanueva H, Bendandi N, Lasarte JJ, Pastor F*. Targeting inhibition of Foxp3 by a CD28 2’-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. Biomaterials. 2016 Jun; 91:73-80

  • Soldevilla MM, Villanueva H, Casares N, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F*. MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells. Oncotarget. 2016;7(17):23182-96.

  • Hervas-Stubbs S, Soldevilla MM, Villanueva H, Mancheño U, Bendandi M, Pastor F*. Identification of TIM3 2’-Fluoro Oligonucleotide Aptamer by HT-SELEX for Cancer Immunotherapy. Oncotarget 2016;7(4):4522-30.

  • Soldevilla MM, Villanueva H, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F *. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials. 2015;67:274-85

  • Gilboa E,* Mc Namara J, Pastor F. Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clinical Cancer Research. 2013 Mar 1;19(5):1054-62

  • Pastor F,* Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R, Klimyuk V, Gleba Y, Gilboa E, Bendandi M. CD28 aptamers as powerful immune response modulators. Mol Ther Nucleic Acids. 2013;2:e98.

  • Pastor F., Kolonias D., McNamara J., Gilboa E.* Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific aptamers. Mol Ther. 2011 Oct 19(10):1878-86.

  • Pastor F., Kolonias D., Giangrande P., Gilboa E. Induction of tumor immunity by targeted inhibition of nonsense mediated mRNA decay. Nature 2010; 465, 227–230.



"One of the most novel applications is the use of aptamers to transport a load in vivo (drugs, siRNA or even another aptamer) to a target cell", Dr. Fernando Pastor, Principal Investigator

Contact

Contact:
Cristina Canciani
Avda. Pío XII, 55
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 2013
canciani@unav.es